Edwards Lifesciences Corporatio vs Merck & Company, Inc. — Stock Comparison
Q·Score Breakdown
7.2
Bullish
Overall
6.7
Neutral
Quality
Health
Growth
Valuation
Sentiment
EW
Clean balance sheet with low leverage (0.1× debt-to-equity).
MRK
Forward P/E of 11.5× is low relative to sector peers.
Analyst Consensus
BUY
Target $97.15 (+15.7%)
27 analysts
BUY
Target $129.74 (+15.7%)
27 analysts
Fundamentals
EW
MRK
45.4×
Trailing P/E
31.5×
25.0×
Forward P/E
11.5×
17.4%
Profit Margin
13.6%
77.9%
Gross Margin
76.6%
—
ROE
—
16.7%
Revenue Growth
4.9%
8.2%
Earnings Growth
—
0.94
Beta
0.28
—
Price / Book
—
$48.4B
Market Cap
$277.0B
$72 – $88
52-Week Range
$73 – $125
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →